Fresenius Medical Care Needs U.S. Volume Growth to Win over Investors

Dow Jones09-29 14:31

0631 GMT - Fresenius Medical Care has made progress on its cost-savings plan, but it might need to return to U.S. volume growth to win over investors, Berenberg analysts say in a research note. The German dialysis specialist has delivered around 920 million euros in savings out of a target of 1.2 billion euros while reducing debt, the analysts say. However, U.S. treatment volumes are weak and deteriorated so far this year after being flat in 2025, they add. This will increasingly drive earnings and investors need evidence of positive U.S. treatment growth for shares to move higher, according to Berenberg. Berenberg cuts its recommendation on Fresenius Medical Care stock to hold from buy, while cutting its target price to 42 euros from 60 euros. Shares closed at 40.48 euros on Monday.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2671296533?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-29 14:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2671296533","market":"us","top_or_hot":-1,"title":"Fresenius Medical Care Needs U.S. Volume Growth to Win over Investors","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>0631 GMT - Fresenius Medical Care has made progress on its cost-savings plan, but it might need to return to U.S. volume growth to win over investors, Berenberg analysts say in a research note. The German dialysis specialist has delivered around 920 million euros in savings out of a target of 1.2 billion euros while reducing debt, the analysts say. However, U.S. treatment volumes are weak and deteriorated so far this year after being flat in 2025, they add. This will increasingly drive earnings and investors need evidence of positive U.S. treatment growth for shares to move higher, according to Berenberg. Berenberg cuts its recommendation on Fresenius Medical Care stock to hold from buy, while cutting its target price to 42 euros from 60 euros. Shares closed at 40.48 euros on Monday.</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fresenius Medical Care Needs U.S. Volume Growth to Win over Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFresenius Medical Care Needs U.S. Volume Growth to Win over Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-09-29 14:31</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>0631 GMT - Fresenius Medical Care has made progress on its cost-savings plan, but it might need to return to U.S. volume growth to win over investors, Berenberg analysts say in a research note. The German dialysis specialist has delivered around 920 million euros in savings out of a target of 1.2 billion euros while reducing debt, the analysts say. However, U.S. treatment volumes are weak and deteriorated so far this year after being flat in 2025, they add. This will increasingly drive earnings and investors need evidence of positive U.S. treatment growth for shares to move higher, according to Berenberg. Berenberg cuts its recommendation on Fresenius Medical Care stock to hold from buy, while cutting its target price to 42 euros from 60 euros. Shares closed at 40.48 euros on Monday.</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISBC","symbol_name":"投资者银行","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2671296533","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2671296533","pubTimestamp":1790663460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0631 GMT - Fresenius Medical Care has made progress on its cost-savings plan, but it might need to return to U.S. volume growth to win over investors, Berenberg analysts say in a research note. The German dialysis specialist has delivered around 920 million euros in savings out of a target of 1.2 billion euros while reducing debt, the analysts say. However, U.S. treatment volumes are weak and deteriorated so far this year after being flat in 2025, they add. This will increasingly drive earnings and investors need evidence of positive U.S. treatment growth for shares to move higher, according to Berenberg. Berenberg cuts its recommendation on Fresenius Medical Care stock to hold from buy, while cutting its target price to 42 euros from 60 euros. Shares closed at 40.48 euros on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ISBC":"投资者银行","BK4211":"区域性银行","FMS":"费森尤斯医疗","BK4196":"保健护理服务"},"translate_title":"费森尤斯医疗保健需要美国销量增长才能赢得投资者的青睐","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1.5,"FMS":0.9},"content_text":"0631 GMT - Fresenius Medical Care has made progress on its cost-savings plan, but it might need to return to U.S. volume growth to win over investors, Berenberg analysts say in a research note. The German dialysis specialist has delivered around 920 million euros in savings out of a target of 1.2 billion euros while reducing debt, the analysts say. However, U.S. treatment volumes are weak and deteriorated so far this year after being flat in 2025, they add. This will increasingly drive earnings and investors need evidence of positive U.S. treatment growth for shares to move higher, according to Berenberg. Berenberg cuts its recommendation on Fresenius Medical Care stock to hold from buy, while cutting its target price to 42 euros from 60 euros. Shares closed at 40.48 euros on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2671296533","isCrawlerRequest":true}